Product Pipeline Progress: Positive clinical trial results or FDA approvals for Intra-Cellular Therapies' drugs, especially Caplyta, often lead to stock price increases. Conversely, setbacks or delays can cause declines. Financial Performance: Strong revenue growth, profitability, and positive earnings reports typically boost investor confidence and drive the stock price higher. Weak financials have the opposite effect. Market Sentiment: Overall investor mood and trends in the biotech and pharmaceutical sectors influence ITCI's stock. Positive sentiment generally lifts prices, while negative sentiment depresses them. Competition: The emergence of new competing drugs or therapies impacts market share and revenue projections, affecting ITCI's stock price. Regulatory Environment: Changes in drug pricing regulations, FDA policies, or healthcare laws can significantly impact Intra-Cellular Therapies' business and stock valuation. Partnerships and Acquisitions: Strategic collaborations, licensing agreements, or acquisitions can signal growth potential and increase ITCI's appeal to investors, impacting the stock price. Economic Conditions: Broader economic factors, such as interest rates, inflation, and overall market stability, can influence investor risk appetite and impact ITCI's stock along with other companies.